Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Amir I, Tukhvatulin"'
Autor:
Inna V. Dolzhikova, Amir I. Tukhvatulin, Daria M. Grousova, Ilya D. Zorkov, Marina E. Komyakova, Anna A. Ilyukhina, Anna V. Kovyrshina, Artem Y. Shelkov, Andrey G. Botikov, Ekaterina G. Samokhvalova, Dmitrii A. Reshetnikov, Andrey E. Siniavin, Daria M. Savina, Dmitrii V. Shcheblyakov, Fatima M. Izhaeva, Alina S. Dzharullaeva, Alina S. Erokhova, Olga Popova, Tatiana A. Ozharovskaya, Denis I. Zrelkin, Polina P. Goldovskaya, Alexander S. Semikhin, Olga V. Zubkova, Andrey A. Nedorubov, Vladimir A. Gushchin, Boris S. Naroditsky, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Vaccines, Vol 12, Iss 10, p 1152 (2024)
Background: The SARS-CoV-2 virus continuously acquires mutations, leading to the emergence of new variants. Notably, the effectiveness of global vaccination efforts has significantly declined with the rise and spread of the B.1.1.529 (Omicron) varian
Externí odkaz:
https://doaj.org/article/5ca4e161630e45b996f7587289d1a662
Autor:
Daria S. Fomina, Marina S. Lebedkina, Anna A. Iliukhina, Anna V. Kovyrshina, Artem Y. Shelkov, Sergey S. Andreev, Anton A. Chernov, Inna V. Dolzhikova, Tatyana S. Kruglova, Gerelma V. Andrenova, Amir I. Tukhvatulin, Dmitry V. Shcheblyakov, Alexander V. Karaulov, Maryana A. Lysenko, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Several virus-neutralizing monoclonal antibodies (mAbs) have become new tools in the treatment of the coronavirus disease (COVID-19), but their effectiveness against the rapidly mutating virus is questionable. The present study investigated the effec
Externí odkaz:
https://doaj.org/article/670820e7fe5d4672ba2d2ca795a32834
Autor:
Amir I. Tukhvatulin, Ilya V. Gordeychuk, Inna V. Dolzhikova, Alina S. Dzharullaeva, Marina E. Krasina, Ekaterina O. Bayurova, Daria M. Grousova, Anna V. Kovyrshina, Alla S. Kondrashova, Daria V. Avdoshina, Stanislav A. Gulyaev, Tatiana V. Gulyaeva, Andrey V. Moroz, Viktoria V. Illarionova, Ilya D. Zorkov, Anna A. Iliukhina, Artem Y. Shelkov, Andrei G. Botikov, Alina S. Erokhova, Dmitry V. Shcheblyakov, Ilias B. Esmagambetov, Olga V. Zubkova, Elisaveta A. Tokarskaya, Daria M. Savina, Yulia R. Vereveyko, Anastasiya S. Ungur, Boris S. Naroditsky, Aydar A. Ishmukhametov, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Emerging Microbes and Infections, Vol 11, Iss 1, Pp 2229-2247 (2022)
Although unprecedented efforts aiming to stop the COVID-19 pandemic have been made over the past two years, SARSCoV-2 virus still continues to cause intolerable health and economical losses. Vaccines are considered the most effective way to prevent i
Externí odkaz:
https://doaj.org/article/8a8e17e744c744cc8415e7fd4b98dfbe
Autor:
Amir I. Tukhvatulin, Inna V. Dolzhikova, Alina S. Dzharullaeva, Daria M. Grousova, Anna V. Kovyrshina, Olga V. Zubkova, Ilya D. Zorkov, Anna A. Iliukhina, Artem Y. Shelkov, Alina S. Erokhova, Olga Popova, Tatiana A. Ozharovskaia, Denis I. Zrelkin, Fatima M. Izhaeva, Dmitry V. Shcheblyakov, Ilias B. Esmagambetov, Elisaveta A. Tokarskaya, Natalia A. Nikitenko, Nadezhda L. Lubenets, Elizaveta A. Khadorich, Vladimir A. Gushchin, Svetlana N. Borzakova, Anna V. Vlasova, Ismail M. Osmanov, Valerii V. Gorev, Boris S. Naroditsky, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
To protect young individuals against SARS-CoV-2 infection, we conducted an open-label, prospective, non-randomised dose-escalation Phase 1/2 clinical trial to evaluate the immunogenicity and safety of the prime-boost “Sputnik V” vaccine administe
Externí odkaz:
https://doaj.org/article/eccefe49c05d44c496a720e9225bf865
Autor:
Amir I. Tukhvatulin, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, Olga V. Zubkova, Alina S. Dzharullaeva, Anna V. Kovyrshina, Nadezhda L. Lubenets, Daria M. Grousova, Alina S. Erokhova, Andrei G. Botikov, Fatima M. Izhaeva, Olga Popova, Tatiana A. Ozharovskaia, Ilias B. Esmagambetov, Irina A. Favorskaya, Denis I. Zrelkin, Daria V. Voronina, Dmitry N. Shcherbinin, Alexander S. Semikhin, Yana V. Simakova, Elizaveta A. Tokarskaya, Maksim M. Shmarov, Natalia A. Nikitenko, Vladimir A. Gushchin, Elena A. Smolyarchuk, Tatiana G. Zubkova, Konstantin A. Zakharov, Vasiliy B. Vasilyuk, Sergei V. Borisevich, Boris S. Naroditsky, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
The Lancet Regional Health. Europe, Vol 11, Iss , Pp 100241- (2021)
Background: While the world is experiencing another wave of COVID-19 pandemic, global vaccination program is hampered by an evident shortage in the supply of licensed vaccines. In an effort to satisfy vaccine demands we developed a new single-dose va
Externí odkaz:
https://doaj.org/article/54fc97d8b69745aa9da8b8b6bf909e3d
Autor:
Daria V. Voronina, Dmitry V. Shcheblyakov, Irina A. Favorskaya, Ilias B. Esmagambetov, Alina S. Dzharullaeva, Amir I. Tukhvatulin, Olga V. Zubkova, Olga Popova, Vladislav Y. Kan, Alina S. Bandelyuk, Maxim M. Shmarov, Denis Y. Logunov, Boris S. Naroditskiy, Aleksandr L. Gintsburg
Publikováno v:
Viruses, Vol 14, Iss 11, p 2485 (2022)
The continued evolution of influenza viruses reduces the effectiveness of vaccination and antiviral drugs. The identification of novel and universal agents for influenza prophylaxis and treatment is an urgent need. We have previously described two po
Externí odkaz:
https://doaj.org/article/55d7dfa81f674cacac3748dcc5023fce
Autor:
Daniele Lapa, Daria M. Grousova, Giulia Matusali, Silvia Meschi, Francesca Colavita, Aurora Bettini, Giulia Gramigna, Massimo Francalancia, Anna Rosa Garbuglia, Enrico Girardi, Vincenzo Puro, Andrea Antinori, Anna V. Kovyrshina, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, Amir I. Tukhvatulin, Olga V. Zubkova, Vladimir A. Gushchin, Denis Y. Logunov, Boris S. Naroditsky, Francesco Vaia, Alexander L. Gintsburg
Publikováno v:
Vaccines, Vol 10, Iss 5, p 817 (2022)
The new Omicron variant of SARS-CoV-2, first identified in November 2021, is rapidly spreading all around the world. Omicron has become the dominant variant of SARS-CoV-2. There are many ongoing studies evaluating the effectiveness of existing vaccin
Externí odkaz:
https://doaj.org/article/ebea215a4c0d4c4698603fbd3fb5e45c
Autor:
Vladimir A. Gushchin, Inna V. Dolzhikova, Alexey M. Shchetinin, Alina S. Odintsova, Andrei E. Siniavin, Maria A. Nikiforova, Andrei A. Pochtovyi, Elena V. Shidlovskaya, Nadezhda A. Kuznetsova, Olga A. Burgasova, Liudmila V. Kolobukhina, Anna A. Iliukhina, Anna V. Kovyrshina, Andrey G. Botikov, Aleksandra V. Kuzina, Daria M. Grousova, Amir I. Tukhvatulin, Dmitry V. Shcheblyakov, Olga V. Zubkova, Oksana V. Karpova, Olga L. Voronina, Natalia N. Ryzhova, Ekaterina I. Aksenova, Marina S. Kunda, Dmitry A. Lioznov, Daria M. Danilenko, Andrey B. Komissarov, Artem P. Tkachuck, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Vaccines, Vol 9, Iss 7, p 779 (2021)
Since the beginning of the 2021 year, all the main six vaccines against COVID-19 have been used in mass vaccination companies around the world. Virus neutralization and epidemiological efficacy drop obtained for several vaccines against the B.1.1.7,
Externí odkaz:
https://doaj.org/article/0b31c283f51e46aabe29d31600c5e309
Autor:
Alina S. Dzharullaeva, Amir I. Tukhvatulin, Alina S. Erokhova, Alina S. Bandelyuk, Nikita B. Polyakov, Andrey I. Solovyev, Natalia A. Nikitenko, Dmitry V. Shcheblyakov, Boris S. Naroditsky, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Journal of Immunology Research, Vol 2018 (2018)
Induction of a robust and long-lived mucosal immune response during vaccination is critical to achieve protection against numerous pathogens. However, traditional injected vaccines are generally poor inducers of mucosal immunity. One of the effective
Externí odkaz:
https://doaj.org/article/d35ea02504f645889a1b12906d5be7da
Autor:
Ilias B. Esmagambetov, Dmitriy V. Shcheblyakov, Daria A. Egorova, Olga L. Voronina, Artem A. Derkaev, Daria V. Voronina, Olga Popova, Ekaterina I. Ryabova, Dmitriy N. Shcherbinin, Ekaterina I. Aksenova, Andrey N. Semenov, Marina S. Kunda, Natalia N. Ryzhova, Olga V. Zubkova, Amir I. Tukhvatulin, Denis Yu. Logunov, Boris S. Naroditsky, Sergey V. Borisevich, Alexander L. Gintsburg
Publikováno v:
Acta Naturae
Ebola fever is an acute, highly contagious viral disease with a mortality rate that can reach 90%. There are currently no licensed therapeutic agents specific to Ebola in the world. Monoclonal antibodies (MAbs) with viral-neutralizing activity and hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2153c3a8f3ff59d5471c7a9d31774bd
https://doi.org/10.32607/actanaturae.11487
https://doi.org/10.32607/actanaturae.11487